TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study: NCT02991534

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CV Toolkit Components
Description: * Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program
Study: NCT00610649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Description: Orally administered capsules containing either 50 mg or 100 mg MK-8777.
Study: NCT04116216

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency repetitive transcranial magnetic stimulation
Description: The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
Study: NCT02785783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRings™
Description: Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
Study: NCT02253082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OctaplasLG®
Description: OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
Study: NCT04116216

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
Study: NCT01153893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM
Description: Intramuscular injection, 1dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: InfanrixTM
Description: Intramuscular injection, 1dose
Study: NCT04362813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
Study: NCT03621306

Intervention type: DEVICE
Intervention: DXA and pQCT precision testing
Description: The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
Study: NCT02253082

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fresh frozen plasma
Description: Standard FFP from the Blood Bank
Study: NCT03990532

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: treatment group(phase I)
Description: Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: treatment group (phase II)
Description: Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
Study: NCT04858841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Oral Product
Description: Administer levetiracetam powder once a day in eligible patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Oral Product
Description: Administer perampanel powder once a day in eligible patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo powder once a day in eligible patients
Study: NCT02882191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LevoCept
Description: placement of LevoCept IUD
Study: NCT00463086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
Study: NCT01206140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02147509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH
Description: Sjogren's Syndrome patients with severe dry eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH, 0.05% CsA
Description: Sjogren's Syndrome patients with severe dry eye
Study: NCT01887964

Intervention type: OTHER
Group type: OTHER
Intervention: RS4 enriched flour
Description: Wheat flour with 30% resistant starch (type-4)

Intervention type: OTHER
Group type: OTHER
Intervention: RS4 enriched flour
Description: Wheat flour with 30% resistant starch (type-4)

Intervention type: OTHER
Group type: OTHER
Intervention: Control flour
Description: Wheat flour without resistant starch (type-4)

Intervention type: OTHER
Group type: OTHER
Intervention: Control flour
Description: Wheat flour without resistant starch (type-4)
Study: NCT03497468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise training
Description: Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
Study: NCT02562846

Intervention type: OTHER
Intervention: Psychological testing and biological sample collection
Description: For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
Study: NCT01803880

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: mechanical shaver that removes areas of damaged tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF-Based Debridement
Description: Electrical energy that removes areas of damaged tissue (Coblation®)
Study: NCT03133494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ABG analysis
Description: ABG analysis was performed and compared between two groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ABG analysis
Description: ABG analysis was performed and compared between two groups
Study: NCT04535973

Intervention type: DIAGNOSTIC_TEST
Intervention: unstimulated saliva sample for hormone analysis
Description: hormone levels will be determined in frozen samples of unstimulated saliva

Intervention type: DIAGNOSTIC_TEST
Intervention: unstimulated saliva sample for hormone analysis
Description: hormone levels will be determined in frozen samples of unstimulated saliva

Intervention type: OTHER
Intervention: quality of life questionnaire
Description: all participants will fill out self-perceived quality of life questionnaire

Intervention type: OTHER
Intervention: quality of life questionnaire
Description: all participants will fill out self-perceived quality of life questionnaire
Study: NCT02508363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Study: NCT02509936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based nutrition education
Description: Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-of-care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care nutrition support
Description: Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
Study: NCT01143961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSC100 - Verso airway access adapter CareFusion
Description: Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
Study: NCT01127984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissucol
Description: dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drainage system
Description: application of vacuum drainage system
Study: NCT04295837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABLE
Description: Home-based occupational therapy compensatory programme addressing activities of daily living

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard occupational therapy
Study: NCT01094834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: tablets, oral administration, multiple administration
Study: NCT02236572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg
Study: NCT01487486

Intervention type: DRUG
Intervention: IVF Antagonist Protocol
Description: 1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval.
Study: NCT02147509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH, tBCL
Description: Sjogren's Syndrome patients with severe dry eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Fm, SH, AS
Description: Sjogren's Syndrome patients with severe dry eye
Study: NCT01488409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: 250 mg by mouth (PO) three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg by mouth (PO) three times daily
Study: NCT02023268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2762
Description: 1 drop in each eye 3 to 6 times daily during 84 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed®
Description: 1 drop in each eye 3 to 6 times daily during 84 days
Study: NCT03163108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop automatic oxygen control (CLAC) fast in addition to RMC
Description: Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop automatic oxygen control (CLAC) slow in addition to RMC
Description: Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
Study: NCT02197520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered subcutaneously (SC), (U-100 formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered subcutaneously (SC), (U-100 formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC), (U-100 formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC), (U-100 formulation)
Study: NCT02402114

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: 120 mg Hydrocortisone given orally one time.
Study: NCT04311788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic self gripping mesh
Description: Prophylactic self gripping mesh, Propgrip by Medtronic.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slowly absorbable continuous monofilament suture
Description: Fascial closure by continuous slowly absorbable 4:1 suture
Study: NCT00673244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
Study: NCT02558231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Macitentan
Description: Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
Study: NCT01250457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical Timolol
Description: topical Timolol 0.5% solution applied twice daily
Study: NCT05768542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Injection
Description: If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5 ml given IV
Study: NCT02469727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will use the FitBit device to track their physical activity
Study: NCT01374295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: watch a 3 minute video
Study: NCT00610649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Description: Orally administered capsules containing either 50 mg or 100 mg MK-8777.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Description: Orally administered capsules containing either 50 mg or 100 mg MK-8777.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Description: Orally administered capsules containing either 50 mg or 100 mg MK-8777.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8777
Description: Orally administered capsules containing either 50 mg or 100 mg MK-8777.
Study: NCT01374295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard education
Description: Receives standard verbal education from healthcare provider
Study: NCT03572166

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arginine infusion
Description: Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline infusion
Description: Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
Study: NCT03579966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Study: NCT04495283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo for APAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo for combination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo for combination
Study: NCT01571076

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PGS
Description: Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: PGS
Description: Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged culture
Description: The embryos will be in prolonged culture and on going embryos transferred on Day 5 .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged culture
Description: Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
Study: NCT03731052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Spray
Description: Topical Spray containing active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Description: Topical Spray containing no active drug
Study: NCT04656808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guilt Focused Intervention
Description: Psychotherapy, group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Psychotherapy, group intervention
Study: NCT01564823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole: 250 mg/8h. 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 250 mg/8h 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine: 2.5 mg/kg of weight/day. 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
Study: NCT02140021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo anal, cervical, vaginal, and oral sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00415441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy program

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo physiotherapy treatment
Study: NCT01806818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirisone 50mg or placebo TID
Description: 3 times a day after meals for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirisone 50mg or placebo TID
Description: 3 times a day after meals for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirisone 50mg or placebo TID
Description: 3 times a day after meals for 1 week